Gemcitabine in the treatment of metastatic pancreatic cancer
A Hilbig, H Oettle - Expert Review of Anticancer Therapy, 2008 - Taylor & Francis
Gemcitabine (2´, 2´-difluorodeoxycytidine) is a deoxycytidine-analog antimetabolite with
broad activity against a variety of solid tumors and lymphoid malignancies. It was approved …
broad activity against a variety of solid tumors and lymphoid malignancies. It was approved …
miR-125 is a Novel Biomarker in Pancreatic Cancer Patients
S Tang - 2014 - d-scholarship.pitt.edu
Approximately 46,420 Americans are diagnosed with pancreatic cancer and 39,590
individuals die from the disease annually. Pancreatic cancer is associated with a less than …
individuals die from the disease annually. Pancreatic cancer is associated with a less than …
Yet another nucleoside analog for pancreatic cancer
V Gandhi - Gastroenterology, 2011 - gastrojournal.org
Although personalized medicine and targeted therapy are attractive treatment options for
patients with cancer, these approaches are not feasible when the pathophysiology of the …
patients with cancer, these approaches are not feasible when the pathophysiology of the …